Showing results (121-130 of 131) with videos related to
Sort By:
Pageof 14
Cell Death & Disease|October 18, 2020
Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancerAnna-Lena Scherr, Andreas Mock, Georg Gdynia, et al.Annals of Surgical Oncology|June 19, 2024
Comparing Survival of Perihilar Cholangiocarcinoma After R1 Resection Versus Palliative Chemotherapy for Unresected Localized DiseaseAnne-Marleen van Keulen, Stefan Buettner, Pim B Olthof, et al.Hepatology (Baltimore, Md.)|January 12, 2020
Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic OpportunitiesBenjamin Goeppert, Trine Folseraas, Stephanie Roessler, et al.Nature Reviews. Gastroenterology & Hepatology|February 9, 2023
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevanceDiego F Calvisi, Luke Boulter, Javier Vaquero, et al.Nature Reviews. Gastroenterology & Hepatology|December 10, 2025
Cholangiocarcinoma 2026: status quo, unmet needs and prioritiesJesus M Banales, Pedro M Rodrigues, Silvia Affò, et al.Neuro-Oncology|July 22, 2025
Distinct molecular profile and outcome of oligodendroglioma, IDH-mutant, 1p/19q-codeleted and TERTp-wildtype: a grade 1 oligodendroglioma of young patients?Filippo Nozzoli, Ramin Rahmanzade, Simone Schmid, et al.Clinical and Translational Medicine|June 15, 2024
Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic markerPatrick S Plum, Timo Hess, Denis Bertrand, et al.Liver International : Official Journal of the International Association for the Study of the Liver|August 19, 2022
Bcl-xL as prognostic marker and potential therapeutic target in cholangiocarcinomaPaula Hoffmeister-Wittmann, Andreas Mock, Federico Nichetti, et al.Hepatology (Baltimore, Md.)|November 2, 2023
Etiology-independent activation of the LTβ-LTβR-RELB axis drives aggressiveness and predicts poor prognosis in HCCAnna-Lena Scherr, Luisa Nader, Kaiyu Xu, et al.Nature|February 4, 2026
Activated ATF6α is a hepatic tumour driver restricting immunosurveillanceXin Li, Cynthia Lebeaupin, Aikaterini Kadianaki, et al.Pageof 14